Projects per year
Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Richard Rupp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age Concomitantly with Routine Pediatr
Rupp, R. (PI)
3/11/25 → 3/10/30
Project: Research project
-
Teen Health Award 2025-2027
Rupp, R. (PI)
Sealy and Smith Foundation ( Award # )
1/1/25 → 12/31/27
Project: Research project
-
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation C in Healthy Adults
Rupp, R. (PI)
Merck Sharp and Cohme Corporation ( Award # )
8/27/24 → 8/26/28
Project: Research project
-
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 4-arm study to investigate the mixed vaccination schedules of a 21-valent pneumococcal conjugate vaccine and a 20-valent pneumococcal conjugate vaccine in healthy infants an
Rupp, R. (PI)
Sanofi Pasteur, Inc ( Award # )
7/19/24 → 7/18/29
Project: Research project
-
Non-Physician Healthcare Workers During COVID-19 Pandemic and Association Between Work-Related Factors, Perceived Stress, Depressive Symptoms, and Fatigue
Mahony, W. L., Ostovar-Kermani, T., Gonzalez, S., Zoorob, R., Rupp, R. E. & Hirth, J., Oct 30 2024, In: Disaster Medicine and Public Health Preparedness. 18, e242.Research output: Contribution to journal › Article › peer-review
Open Access -
Progress with COVID vaccine development and implementation
Titball, R. W., Bernstein, D. I., Fanget, N. V. J., Hall, R. A., Longet, S., MacAry, P. A., Rupp, R. E., van Gils, M., von Messling, V., Walker, D. H. & Barrett, A. D. T., Apr 1 2024, In: npj Vaccines. 9, 1, p. 69 69.Research output: Contribution to journal › Editorial › peer-review
Open Access1 Scopus citations -
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial
Borys, D., Rupp, R., Smulders, R., Chichili, G. R., Kovanda, L. L., Santos, V., Malinoski, F., Siber, G., Malley, R. & Sebastian, S., Apr 11 2024, In: Vaccine. 42, 10, p. 2560-2571 12 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial
the DMID 17-0090 Study Group, Feb 15 2024, In: Journal of Infectious Diseases. 229, 2, p. 327-340 14 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine
Ye, X., Shih, D. J. H., Ku, Z., Hong, J., Barrett, D. F., Rupp, R. E., Zhang, N., Fu, T. M., Zheng, W. J. & An, Z., Apr 1 2024, In: npj Vaccines. 9, 1, p. 70 70.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations